(Q44789126)

6 December 2017

Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008. (English)

1 reference

6 December 2017

0 references

1 reference

3

1 reference

6 December 2017

Cheryl Cohen

2

0 references

Anne von Gottberg

series ordinal

1

object named as

Anne von Gottberg

1 reference

6 December 2017

8

Shabir A Madhi

1 reference

6 December 2017

Susan Meiring

4

0 references

Keith P. Klugman

series ordinal

10

object named as

Keith P Klugman

1 reference

6 December 2017

9

Cynthia G Whitney

1 reference

6 December 2017

5

Vanessa Quan

1 reference

PubMed ID

23684826

6 December 2017

Penny Crowther-Gibson

series ordinal

7

object named as

Penny Crowther-Gibson

1 reference

6 December 2017

Andrew Whitelaw

6

1 reference

PubMed ID

23684826

6 December 2017

language of work or name

English

0 references

publication date

16 May 2013

1 reference

6 December 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

6 December 2017

31

1 reference

6 December 2017

4200-4208

1 reference

6 December 2017

38

1 reference

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

6 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Serotype 6C is associated with penicillin-susceptible meningeal infections in human immunodeficiency virus (HIV)-infected adults among invasive pneumococcal isolates previously identified as serotype 6A in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Bacteremia among children admitted to a rural hospital in Kenya.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Pneumococcal disease among children in a rural area of west Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

The preventable burden of pneumococcal disease in the developing world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Pneumococcal bacteremia during a decade in children in Soweto, South Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Population Snapshot of EmergentStreptococcus pneumoniaeSerotype 19A in the United States, 2005

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

inferred from DOI database lookup

7 January 2021

based on heuristic

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Increased risk of death in human immunodeficiency virus-infected children with pneumococcal meningitis in South Africa, 2003-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.077

10.1016/J.VACCINE.2013.04.077

7 January 2021

Identifiers

DOI

1 reference

6 December 2017

1 reference

PubMed ID

23684826